ABOUT HA-REACT

  • HA-REACT structure overview

The Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) addresses existing gaps in the prevention of HIV and other co-infections, especially tuberculosis (TB) and viral hepatitis, among people who inject drugs (PWID). The three-year project was launched in late 2015 with core funding by the Health Programme 2014-2020 from European Union (EU). Twenty-two partners representing 18 EU Member States are currently implementing the project. Additional expertise is provided by 14 collaborating partners, including the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The HA-REACT project has been carried out in three focus countries: Latvia, Lithuania and Hungary. However, materials developed as part of the Joint Action will be of benefit to the entire European Union.

KEY FACTS

  • Budget: approx. EUR 3,75 million co-funded by the Health Programme of the European Union
  • Duration: October 2015 – January 2019
  • Coordination: National Institute for Health and Welfare (THL), Finland
  • Partners: 22 partners from 18 countries
  1. Associated Partners
  2. Collaborating Partners
  3. Main Objectives
  4. Advisory Board

1. HA-REACT ASSOCIATED PARTNERS

  • Croatia. Croatian Institute of Public Health (Hrvatski Zavod Za Javno Zdravstvo)
  • Croatia. Life Quality Improvement Organisation - NGO FLIGHT (Udruga Za Unapredenje Kvalitete Zivljenja)
  • Czech Republic. National Monitoring Centre for Drugs and Addiction (Urad Vlady Ceske Republiky)
  • Denmark. Centre for Health and Infectious Disease Research, Rigshospitalet, University of Copenhagen
  • Estonia. National Institute for Health Development (Tervise Arengu Instituut)
  • Finland. Health and Welfare (Terveyden Ja Hyvinvoinnin Laitos)
  • Greece. Hellenic Center for Disease Control Αnd Prevention (Kentro Eleghou & Prolipsis Nosimaton)
  • Germany. Center of Interdisciplinary Addiction Research (Zentrum fur interdisziplinare Suchtforschung der Universitaet Hamburg)
  • Germany. Institut fur Suchtforschung
  • Germany. Deutsche AIDS-Hilfe
  • Germany. AIDS Action Europe
  • Hungary. National Centre for Epidemiology (Országos Epidemiológiai Központ)
  • Hungary. Office of the Chief Medical Officer (Országos Tisztifőorvosi Hivatal)
  • Iceland. Landspitali University Hospital
  • Italy. National Institute for Infectious Diseases (Istituto Nazionale Malattie Infettive L. Spallanzani)
  • Latvia. Center For Disease Prevention and Control (Slimibu Profilakses Un Kontroles Centrs)
  • Lithuania. Centre for Communicable Diseases and AIDS (Uzkreciamuju Ligu Ir Aids Centras)
  • Lithuania. Vilnius Centre for Addictive Disorders (Vilniaus Priklausomybes Ligu Centras)
  • Luxembourg. Directorate of Health – Division of Sanitary Inspection (Ministere De La Sante)
  • Malta. Ministry for Health
  • Poland. National AIDS Centre (Krajowe Centrum ds. AIDS)
  • Portugal. Directorate-General of Health (Ministerio Da Saude)
  • Slovenia. Association SKUC (Drustvo Studentski Kulturni Center)
  • Spain. Instituto de Salud Carlos III, Biomedical Research Networking Centres (CIBER)

All contacts are listed on our partners list.

2. HA-REACT COLLABORATING PARTNERS

  • AIDS Foundation East-West 
  • Coordinadora Estatal de VIH-SIDA, Spain
  • Czech AIDS Help Society
  • Department of Health, London, United Kingdom
  • European Centre for Disease Prevention and Control
  • European Monitoring Centre for Drugs and Drug Addiction
  • Free Clinic, Belgium
  • Grupo de Ativistas em Tratamentos, Portugal
  • Medical and Public Health Services of the Ministry of Health of the Republic
  • of Cyprus
  • Ministry of Health, Czech Republic
  • National Institute of Public Health, Czech Republic
  • Norwegian Institute of Public Health
  • Public Health Agency of Sweden
  • Vilnius University, Lithuania

CESIDA, ECDC, EMCDDA and Free Clinic

3. HA-REACT MAIN OBJECTIVES

WORKING TOGETHER to prevent HIV, viral hepatitis and tuberculosis among people who use drugs in Europe:

  • To improve countries’ capacity to respond to HIV and co-infection risks, and provide harm reduction measures, focusing specifically on PWID.
  • To focus on European Union member states where there are obvious barriers to effective and evidence-based interventions, or where such interventions are not sufficiently implemented.
  • To encourage the implementation of comprehensive harm reduction in all EU Member States, as an essential strategy to improve the prevention and treatment of HIV, TB and viral hepatitis.

The overall aim of HA-REACT is to significantly contribute to the elimination of HIV and to reduce the number of cases of TB and viral hepatitis among PWID in the European Union by 2020. This objective aligns with strategic action plans issued by the European Union, World Health Organization, UNAIDS and the United Nations Office on Drugs and Crime (UNODC).

 4. HA-REACT ADVISORY BOARD

The Advisory Bord is a supporting body for the Steering Committee of the The HA-REACT Joint Action. It is governed by 15 members:

  • CHAFEA: Cinthia Menel Lemos
  • DG SANTE: Velina Pendolovska
  • DG HOME: Paola Mazzarini
  • ECDC: Anastasia Pharris
  • EMCDDA: Dagmar Hedrich
  • WHO/EURO: Martin Donoghoe
  • Civil Society Forum on Drugs/Correlation Network: Eberhard Schatz
  • Civil Society Forum on HIV/AIDS: Luís Mendao
  • European network of people  who use drugs (EuroNPUD): to be nominated
  • Eurasian Harm Reduction Association (EHRA): Anna Dovbakh
  • European Association for the Study of the Liver (EASL): Helena Cortez-Pinto (Alternate: Fiona Godfrey)
  • European Liver Patients Association (ELPA): Milan Mishkovikj
  • NDPHS Expert Group on HIV, TB and Associated Infections: Hans Blystad
  • UNODC: Monica Beg (Alternate Fabienne Hariga)
  • European Forum for Primary Care: Katerina Venovska

For further information about HA-REACT Joint Action, please contact Outi Karvonen (outi.karvonen@thl.fi, +358 29 524 7046, Project Manager HA-REACT Joint Action on HIV and Co-infection Prevention and Harm Reduction, National Institute for Health and Welfare (THL)).  

For further questions about this website, please contact Jeffrey Lazarus (jeffrey.lazarus@regionh.dk, CHIP, University of Copenhagen) or Ljuba Böttger (ljuba.boettger@aidsactioneurope.org, +49 30 69008793, Communications Coordinator, AIDS Action Europe).

Twitter News